Results 21 to 30 of about 2,071 (176)

Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies [PDF]

ACR Open Rheumatology
Objective The objective of this study was to assess 52‐week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/−MTX) treatment at baseline.
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B. Gottlieb   +10 more
doaj   +2 more sources

Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient

Dermatology and Therapy
This article explores the ongoing research into the complex pathogenesis of hidradenitis suppurativa (HS) and the persistent challenges in finding effective treatments. With 113 clinical studies currently listed on ClinicalTrials.gov, the quest for novel
Fabrizio Martora, Teresa Battista, Luca Potestio, Matteo Megna   +3 more
doaj   +2 more sources

Real World Evidence of Secukinumab and Bimekizumab in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

Actas Dermo-Sifiliográficas
Background and objectives: Evidence for secukinumab and bimekizumab in hidradenitis suppurativa (HS) primarily comes from randomized clinical trials with selected patient populations.
S. Haselgruber, D. Muñoz-Barba, A. Soto-Moreno, C. Cuenca-Barrales, S. Arias-Santiago, A. Molina-Leyva   +5 more
doaj   +2 more sources

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies [PDF]

Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and ...
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates   +13 more
doaj   +2 more sources

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years [PDF]

Arthritis Research & Therapy
Background Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to 2 years in patients with axial spondyloarthritis (axSpA).
Sofia Ramiro, Fabian Proft, Raj Sengupta, Astrid van Tubergen, Anna Moltó, Lianne S. Gensler, Mitsumasa Kishimoto, Vanessa Taieb, Sarah Kavanagh, Shawna Evans, Victoria Navarro-Compán   +10 more
doaj   +2 more sources

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Dermatology and Therapy, 2023
Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study.
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa   +11 more
doaj   +1 more source

SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis

, 2023
Objectives: To compare the relative efficacy and safety of bimekizumab, a selective inhibitor of interleukin (IL)-17F in addition to IL-17A, against approved biologic- and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) for ...
D. Willems, Mease, PJ, D.D. Gladman, Taieb, V, J.F Merola, L.C Coates, Willems, D, Nash, P, P.J Mease, A.R Prickett, Laliman-Khara, V, P. Nash, V. Laliman-Khara, Coates, LC, Prickett, AR, S. Grieve, Gladman, DD, Grieve, S, V. Taieb, Merola, JF   +19 more
core   +1 more source

Bimekizumab for recalcitrant pyoderma gangrenosum. [PDF]

JAAD Case Rep
Tolete C, Friedman A, Calderon J, Tjahjono L.   +3 more
europepmc   +4 more sources

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

RMD Open
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double ...
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya   +17 more
doaj   +3 more sources

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Drugs in Context, 2021
Bimekizumab, a humanized monoclonal IgG1 antibody being currently evaluated for multiple immune-mediated diseases, is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021.
Egídio Freitas, Tiago Torres
doaj   +1 more source